Dolby Laboratories, Inc.
For the period ended Jun 26, 2026. Filed Jul 30, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 26, 2026 · Filed Jul 30, 2026
DLB$64.67-0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Interim Condensed Consolidated Balance Sheets
INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share amounts)
| June 26,2026 | September 26,2025 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $669,394 | $701,893 |
| Restricted cash | 69,492 | 91,468 |
| Short-term investments | 652 | 703 |
| Accounts receivable, net of allowance for credit losses of $9,593 and $7,221 | 285,148 | 331,096 |
| Contract assets, net of allowance for credit losses of $94 and $101 | 206,881 | 180,804 |
| Inventories, net | 30,768 | 30,424 |
| Prepaid expenses and other current assets | 63,706 | 51,873 |
| Total current assets | 1,326,041 | 1,388,261 |
| Long-term investments | 86,437 | 80,205 |
| Property, plant, and equipment, net | 459,115 | 470,608 |
| Operating lease right-of-use assets | 42,401 | 33,204 |
| Intangible assets, net | 382,434 | 397,057 |
| Goodwill | 528,343 | 529,900 |
| Deferred taxes | 213,171 | 214,361 |
| Other non-current assets | 118,660 | 114,164 |
| Total assets | $3,156,602 | $3,227,760 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $12,470 | $17,840 |
| Accrued liabilities | 360,407 | 369,256 |
| Income taxes payable | — | 8,928 |
| Contract liabilities | 33,593 | 31,382 |
| Operating lease liabilities | 9,859 | 10,384 |
| Total current liabilities | 416,329 | 437,790 |
| Non-current contract liabilities | 23,463 | 29,687 |
| Non-current operating lease liabilities | 37,591 | 28,494 |
| Other non-current liabilities | 86,504 | 99,843 |
| Total liabilities | 563,887 | 595,814 |
| Commitments and Contingencies (See Note 15) | ||
| Stockholders’ equity: | ||
| Class A, $0.001 par value, one vote per share, 500,000,000 shares authorized: 59,393,554 shares issued and outstanding as of June 26, 2026 and 60,802,616 as of September 26, 2025 | 52 | 54 |
| Class B, $0.001 par value, ten votes per share, 500,000,000 shares authorized: 34,251,901 shares issued and outstanding as of June 26, 2026 and 34,660,045 as of September 26, 2025 | 40 | 40 |
| Retained earnings | 2,598,923 | 2,634,980 |
| Accumulated other comprehensive loss | (15,468) | (12,517) |
| Total stockholders’ equity – Dolby Laboratories, Inc. | 2,583,547 | 2,622,557 |
| Noncontrolling interest | 9,168 | 9,389 |
| Total stockholders’ equity | 2,592,715 | 2,631,946 |
| Total liabilities and stockholders’ equity | $3,156,602 | $3,227,760 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.